Please assess the completion status of the following clinical trial:

Trial Title: DS-5565 Phase III Study for Post-herpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* PHN defined as pain present for more than 3 months after herpes zoster skin rash at screening~* At screening, a pain scale of ≥ 40 mm~Exclusion Criteria:~* Previous use of neurolytic block

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (14-weeks)
- DS-5565 15 mg Group (Type: EXPERIMENTAL): DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
- DS-5565 20 mg Group (Type: EXPERIMENTAL): DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
- DS-5565 30 mg Group (Type: EXPERIMENTAL): DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose

Based on this trial design, predict the completion outcome and termination type (if applicable).